Gi Dynamics Inc (GIDYL) 0.1800 $GIDYL
GI Dynamics Resumes Shipments of EndoBarrier(R) Product
Business Wire - Mon Dec 01, 5:30AM CST
GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that its Notified Body in the European Union, an organization that has been accredited by Member States to assess whether a product meets the requirements of the EU Medical Device Directive 93/42/EEC, has cleared the Company to resume commercial product shipments. Today's decision by the Notified Body will permit the Company to resume commercial activities in all jurisdictions where it was previously selling EndoBarrier(R).
Global Bariatric Surgery Devices Market 2014-2018: Key Vendors are Allergan, Covidien, Ethicon-Endosurgery and Olympus
M2 - Thu Oct 09, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q5bgbt/global_bariatric) has announced the addition of the "Global Bariatric Surgery Devices Market 2014-2018" report to their offering. Obesity is a medical condition wherein there is an excess accumulation of body fat. According to the World Health Organization (WHO), person having body mass index (BMI) of 30 or more is generally considered as obese. It has been characterized as an epidemic. Obesity in children and adults is associated with serious health risks that include hypertension, dyslipidemia, diabetes, fatty liver disease, obstructive sleep apnea, and psychosocial complications. Bariatric surgery is the treatment procedure used to treat obesity. Bariatric surgery devices used are different depending on the type of bariatric procedure being performed. The analysts forecast the Global Bariatric Surgery Devices market to grow at a CAGR of 8.21 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Bariatric Surgery Devices market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sale of bariatric surgery devices. The report, the Global Bariatric Surgery Devices Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Procedure 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Allergan - Covidien - Ethicon-Endosurgery - Olympus - Agency of Medical Innovations - Applied Medical Resources - EndoGastric Solutions - GI Dynamics - Intuitive Surgical - Medtronic - PARE Surgical - Peters-Surgical SAS - ReShape Medical - Spartz FGIA - Surgical IOC - TransEnterix For more information visit http://www.researchandmarkets.com/research/q5..._bariatric
ISRG: 510.73 (+3.02), AGN: 229.49 (+1.87), MDT: 75.26 (+0.33)
GI Dynamics, Inc. Announces the Appointment of Medical Device Industry Veteran Michael D. Dale as President & Chief Executive Officer
Business Wire - Thu Aug 28, 8:05AM CDT
GI Dynamics, Inc. (ASX:GID) today announced the appointment of Michael D. Dale as President, CEO and member of the Board of Directors of GI Dynamics, effective September 18, 2014. Mr. Dale will replace Stuart A. Randle, who will be stepping down as President and CEO, but will remain on the Board and available as a consultant during a transition period. Mr. Dale brings more than 25 years of executive experience successfully driving growth and delivering financial results in dynamic, innovative public and private medical device organizations.
GI Dynamics Announces Departure of Chief Commercial Officer
Business Wire - Tue Jul 01, 5:46PM CDT
GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, announced that Mark C. Twyman is leaving his position as chief commercial officer, effective today. GI Dynamics has launched a search for a president and chief operating officer to augment its leadership team and oversee the global sales and marketing efforts for EndoBarrier(R) Therapy. In the interim, other members of senior management will assume Mr. Twyman's responsibilities.
Data Presented at ADA Show the Effects of GI Dynamics' EndoBarrier(R) Therapy on Glycemic Control and Reducing Diabetes Medication in Patients with Type 2 Diabetes and Obesity
Business Wire - Mon Jun 16, 5:30AM CDT
GI Dynamics, Inc. (ASX:GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced data findings from presentations that further demonstrate the acute effects of EndoBarrier(R) Therapy on glycemic control, its ability to reduce reliance on diabetes medications, including insulin, as well as findings that help explain its potential mechanism of action. These findings were presented in three poster presentations at the 74th Scientific Sessions of the American Diabetes Association in San Francisco.
BIND Therapeutics to Present at 26th Annual Roth Conference
Business Wire - Wed Feb 26, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the 26th Annual Roth Conference in Laguna Nigel, CA on Monday, March 10, 2014 at 11:30 a.m. PT.
BIND: 6.06 (+0.21)
GI Dynamics Resumes Shipments of EndoBarrier(R) Product
Business Wire - Mon Dec 01, 5:30AM CST
GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that its Notified Body in the European Union, an organization that has been accredited by Member States to assess whether a product meets the requirements of the EU Medical Device Directive 93/42/EEC, has cleared the Company to resume commercial product shipments. Today's decision by the Notified Body will permit the Company to resume commercial activities in all jurisdictions where it was previously selling EndoBarrier(R).
Global Bariatric Surgery Devices Market 2014-2018: Key Vendors are Allergan, Covidien, Ethicon-Endosurgery and Olympus
M2 - Thu Oct 09, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q5bgbt/global_bariatric) has announced the addition of the "Global Bariatric Surgery Devices Market 2014-2018" report to their offering. Obesity is a medical condition wherein there is an excess accumulation of body fat. According to the World Health Organization (WHO), person having body mass index (BMI) of 30 or more is generally considered as obese. It has been characterized as an epidemic. Obesity in children and adults is associated with serious health risks that include hypertension, dyslipidemia, diabetes, fatty liver disease, obstructive sleep apnea, and psychosocial complications. Bariatric surgery is the treatment procedure used to treat obesity. Bariatric surgery devices used are different depending on the type of bariatric procedure being performed. The analysts forecast the Global Bariatric Surgery Devices market to grow at a CAGR of 8.21 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Bariatric Surgery Devices market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sale of bariatric surgery devices. The report, the Global Bariatric Surgery Devices Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Procedure 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Allergan - Covidien - Ethicon-Endosurgery - Olympus - Agency of Medical Innovations - Applied Medical Resources - EndoGastric Solutions - GI Dynamics - Intuitive Surgical - Medtronic - PARE Surgical - Peters-Surgical SAS - ReShape Medical - Spartz FGIA - Surgical IOC - TransEnterix For more information visit http://www.researchandmarkets.com/research/q5..._bariatric
ISRG: 510.73 (+3.02), AGN: 229.49 (+1.87), MDT: 75.26 (+0.33)
GI Dynamics, Inc. Announces the Appointment of Medical Device Industry Veteran Michael D. Dale as President & Chief Executive Officer
Business Wire - Thu Aug 28, 8:05AM CDT
GI Dynamics, Inc. (ASX:GID) today announced the appointment of Michael D. Dale as President, CEO and member of the Board of Directors of GI Dynamics, effective September 18, 2014. Mr. Dale will replace Stuart A. Randle, who will be stepping down as President and CEO, but will remain on the Board and available as a consultant during a transition period. Mr. Dale brings more than 25 years of executive experience successfully driving growth and delivering financial results in dynamic, innovative public and private medical device organizations.
GI Dynamics Announces Departure of Chief Commercial Officer
Business Wire - Tue Jul 01, 5:46PM CDT
GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, announced that Mark C. Twyman is leaving his position as chief commercial officer, effective today. GI Dynamics has launched a search for a president and chief operating officer to augment its leadership team and oversee the global sales and marketing efforts for EndoBarrier(R) Therapy. In the interim, other members of senior management will assume Mr. Twyman's responsibilities.
Data Presented at ADA Show the Effects of GI Dynamics' EndoBarrier(R) Therapy on Glycemic Control and Reducing Diabetes Medication in Patients with Type 2 Diabetes and Obesity
Business Wire - Mon Jun 16, 5:30AM CDT
GI Dynamics, Inc. (ASX:GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced data findings from presentations that further demonstrate the acute effects of EndoBarrier(R) Therapy on glycemic control, its ability to reduce reliance on diabetes medications, including insulin, as well as findings that help explain its potential mechanism of action. These findings were presented in three poster presentations at the 74th Scientific Sessions of the American Diabetes Association in San Francisco.
BIND Therapeutics to Present at 26th Annual Roth Conference
Business Wire - Wed Feb 26, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the 26th Annual Roth Conference in Laguna Nigel, CA on Monday, March 10, 2014 at 11:30 a.m. PT.
BIND: 6.06 (+0.21)
